<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:Palatino;
color:windowtext;
font-weight:normal;
font-style:normal;}
span.EmailStyle19
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle20
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:#1F497D;}
span.EmailStyle21
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1047532504;
mso-list-template-ids:352232678;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1382168442;
mso-list-template-ids:-376303360;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D246.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=Z3xOyV3JHDKuHp7SPOMwcDoqa4TPEtx6rSUx6KnahwU&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance
Abuse and Addiction Scientists (R25 – Clinical Trials Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational
activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will
support creative educational activities with a primary focus on:<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><i><span style="font-size:12.0pt;font-family:Palatino">Research Experiences</span></i></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><b><i><span style="font-size:12.0pt;font-family:Palatino">Courses for Skills Development</span></i></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This NIDA R25 Education Program will provide the resources needed to assist with the preparation of individuals from diverse backgrounds to successfully transition to the subsequent
professional career stage. This FOA invites applications from established researchers with a record of NIH funding, who can demonstrate that they have successfully guided previous early career scientists to independent research careers and are able to direct
an educational research capacity building program. This program intends to strengthen the pipeline of individuals in biomedical, behavioral, and clinical substance abuse and addiction research across various stages of the research pipeline to enhance the number
of independently funded investigators from diverse backgrounds, including from underrepresented groups.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">NIDA also expects that efforts and resources from this program will also foster a greater understanding of the implications of substance abuse and addiction nationwide and
contribute to the biomedical research workforce which will help to develop solutions to reduce the burden of substance abuse, addiction, and their health-related consequences across all populations. To that end, NIDA encourages research experiences to include,
but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, pain and analgesia, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, delivery of HIV
and substance abuse prevention and treatment services, medication development, epidemiology of substance abuse, and implementation science, including secondary data analysis. In addition, American Indians and Alaska Natives experience tremendous disparities
in substance abuse and addiction, having the highest rates of abuse and addiction relative to other racial/ethnic groups, and experience high rates of negative consequences from substance abuse. Research addressing American Indian and Alaska Native substance
abuse and addiction health related disparities is particularly encouraged.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">A milestone plan with timelines and metrics is required for all applications. The detailed milestone plan will be used to evaluate the application during peer review and in
consideration of the awarded project for funding of non-competing award years. The milestone plan will be used to evaluate the research experiences and technical training of participants; formal mentoring plans and professional career development activities
completed by participants; NIH application and manuscript submissions from participants; courses for skills development offered, participant participation, and feedback; and when appropriate, the successful graduation or transition of participants to the subsequent
career stage. Applicants can focus on a single career stage or encompass multiple career stages (undergraduate students, predoctoral students, postdoctoral fellows, and/or early-stage investigators) within their approach, but must include research experiences,
and courses for skills development to prepare participants to successfully transition to the subsequent professional career stage as components of the program.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due June 12, 2019; July 15, 2020; and July 15, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for 2019 date: May 29.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__onemind.org_wp-2Dcontent_uploads_2019_03_2019-2DOne-2DMind-2DRising-2DStar-2DResearch-2DAwards-2DRFP.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=1NHyFm5cGoHC9x7sVXR-Zj6QEO1MGAngiXbpuc3ePXA&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">One Mind Rising Star Research Awards: Accelerate Research on
Major Neuropsychiatric Disorders</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This program seeks to fund research directed at understanding the fundamental characteristics and biological mechanisms of brain function and dysfunction, as well as the translation
of basic science mechanisms into better diagnostics and treatments for neuropsychiatric disorders. Of particular interest is research dedicated to
<b>schizophrenia and/or depression</b>. Studies that use exiting data and collaborations to accelerate discovery and knowledge also are encouraged. Examples of relevant research through this opportunity include but are not limited to studies focused on the
biological mechanisms of neuropsychiatric and/or neurotraumatic disorder(s); the identification of pharmacological and non-pharmacological therapeutic targets; the development of new or refinement of existing models for studying neuropsychiatric and/or neurotraumatic
disorders; the development of new or improvement of existing tools for studying brain health; the identification or advancement of biomarker development for neuropsychiatric disorder(s); the development of targeted therapies to prevent the onset or progression
of neuropsychiatric disorders, mitigate their negative effects on brain function and behavior, and/or promote recovery; the characterization of similarities and differences in biological mechanisms between two or more neuropsychiatric disorders, and/or characterization
of the effects of comorbid conditions on diagnosis, prognosis, and treatments; the external validation of promising biomarkers, diagnostic tools, and treatments; a comparison of the effects of treatments on whole or select patient populations; and the generation
of new hypotheses from existing clinical data and their testing in relevant preclinical or computational models, or in small pilot clinical studies.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Applicants whose proposals can be enhanced with
<b>optical methods</b> to investigate links between neural circuit/ensemble dynamics and disease phenotypes are encouraged to
<b>apply for a supplemental technology grant from Inscopix</b>. Proposals within this category might include but are not limited to signal analysis in health vs. disease, and/or how circuit/ensemble signatures change and evolve during disease progression and
in therapeutic intervention paradigms; studies that use established or new rodent models of neuropsychiatric disorders to extract key characteristics of the pathophysiology in a cell type- and/or circuit-specific manner; and investigations into the causal
role of disease circuit/ensemble dynamics identified with nVoke/nVista and potentially in conjunction with other methods such as pharmacology, chemogenetics, electrophysiology, and cell ablation. Up to five award recipients will receive $250,000 over three
years. In addition, up to three supplemental technology grants will be awarded, with each including a state of the art nVoke miniature microscope system, full scientific support, and full technical support. Applicants may apply for the technology grant only
as a supplement to a Rising Star Award proposal and cannot apply for the technology grant by itself.
<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">To be eligible, candidates should be
<b>within ten years of their initial independent appointment</b> and have demonstrated productivity and innovation in a scientific field that can be applied to the study of neuropsychiatric disorders such as attention-deficit hyperactivity disorder (ADHD),
anxiety, addiction, bipolar disorder, depression, post-traumatic stress, schizophrenia, traumatic brain injury, digital therapies, or other field relevant to brain health.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due May 15, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 1.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.alexslemonade.org_sites_default_files_2019-5Fa-2Daward-5Fguidelines-5Ffinal-5F0.pdf&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=jjk0VscxxrgepltMEWhEw3srfZpZNOuV9_4ObtBIU2k&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Alex’s Lemonade Stand: ‘A’ Awards</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The foundation is currently accepting applications for its ‘A’ Award. Through the program, a grant of up to $800,000 over four years will be awarded to an independent early-career
researcher seeking to establish a career in pediatric oncology research who has demonstrated a future commitment to pediatric cancer investigation and has institutional support for his/her career development. The ideal applicant should have original research
that is not currently being funded, with the goal of advancing knowledge that will lead to new treatments and cures for children with cancer. Eligible applicants must have an MD, PhD, or dual MD PhD (DO, MBBS, or equivalent) and be within five years of their
first faculty appointment as an assistant professor. Applicants may have research grants from other funding sources during the ‘A’ Award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap. Investigators cannot
have a K99/R00 or an R01 that has been funded, or have been recommended for such funding (i.e., expect to be funded), at the time they apply.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due May 20, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 6.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DNS-2D19-2D028.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=wJeCyfvNZSnYZLSKevFBS1Av-UGTuyalEYUVNyl99A0&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Accelerating Medicine Partnership in Parkinson’s disease (AMP PD) unbiased proteomics biofluid
analysis (U01 Clinical Trials Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of the FOA is to support unbiased proteomics analysis of matched longitudinal CSF and plasma samples from Accelerating Medicine Partnership in Parkinson's disease
(AMP PD) cohorts using a data independent acquisition (DIA) mass spectrometry platform, with the ultimate goal of identifying PD biomarkers for diagnosis, prognosis and progression. Proteomics data generated through this initiative will be broadly shared with
the research community through the AMP PD Knowledge Portal to enable additional analyses and data integration across the various datatypes available through AMP PD. A staged approach will be used to first identify and address pre-analytical variables and then
incorporate that information into the optimal design for the analysis of 4500 CSF and plasma samples.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due May 29, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: May 14.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D247.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=H4CKgeFrAc37w0XKxDOJFLLAiWwuBaxarpBs_FEtOyE&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R21</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D248.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=nFO89Fi-p-iDGA34LkjltvaINKBsIALFfVKMqTU3rQ8&e="><span style="font-size:12.0pt;font-family:Palatino">R01</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of these Funding Opportunity Announcements is to support research to improve existing animal models or develop novel animal models that more accurately represent
influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due June 18, 2019; June 18, 2020; and June 18, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for 2019 date: June 4.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DAI-2D19-2D017.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=DZpSG0vWDfTbkmAfd7CnEvKQp-YgyF9nbiGP6ap1L3E&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Development of Sample Sparing Assays for Monitoring Immune Responses (U24 Clinical Trial Not
Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement is to accelerate the development and validation of sample sparing assays that can be applied for studying the human immune
system in health and disease. Development of new, cutting-edge sample sparing assays will lead to maximum use of the human-derived specimens by significant reduction of sample volumes/amounts required or by simultaneous multi-parameter assessments of immune
function.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due July 30, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: July 16.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D223.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=BR3-LmXN2SNdpNtfADPptYtUWKZB78dx-gRAXHCMGhM&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those
in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS
research and the other for genetics or epigenetics studies. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics
or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches
to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being
tomorrow's leaders in the field of genetics or epigenetics of substance use disorders.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due October 21, 2019; October 19, 2020; and October 19, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for 2019 date: October 7.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D229.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=bnI-v-Aqg36ZWJlHWBye7X5dnQdw3jYzDCRSAAAQpls&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Informatics Methodology and Secondary Analyses for Immunology Data in ImmPort (UH2 Clinical Trial
Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The goals of this Funding Opportunity Announcement are to support the development of new or improved informatics tools and methods for the reuse of shared data in the immunology
study repository, ImmPort, and to support secondary analyses of existing immunology datasets to address basic and clinical immunology questions.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due October 1, 2019; October 1, 2020; and October 1, 2021.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for 2019 date: September 17.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PA-2D19-2D230.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=ldJ7l5pFYZHsxxsTth1zvoilNB4MI5GqKlT6vSGgGjM&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Pragmatic clinical trial on efficacy of managing reduced iron stores on risk of clinically important
events in older adults with heart failure and anemia (U01 Clinical Trial Required)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This FOA invites applications for a pragmatic clinical trial to establish efficacy of managing reduced iron stores on risk of clinically important events in older adults with
heart failure and anemia.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires July 6, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 2019 date: May 22.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Reducing the Duration of Untreated Psychosis in the United States (R34 / R01 Clinical Trial Required)<o:p></o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D235.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=hhQpwfd3OLpeZ7OUlgVEK58hysBmquGAqUQiKeW8Rwo&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R34</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D236.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=h_BSwvuQA5XmgwcrzmKHMi-_1wVjabfvtwPV6lvPIdg&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">R01</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely
viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset
of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based Coordinated Specialty Care (CSC) for early psychosis, and effective
engagement in CSC services are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly,
the R34 Funding Opportunity Announcement (FOA) seeks planning research project grant applications that (1) identify a baseline rate of DUP in community or institutional settings; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the
pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP. Alternatively, applicants who have already completed significant developmental or pilot work in this area are encouraged to apply
to the companion R01 FOA.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires May 8, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 2019 date: May 22.<o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black"> <o:p></o:p></span></b></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PA-2D19-2D237.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=0sQ3XDuSXg4sxLQEjbGiuGe9UvJvUULS7deFY77mwB4&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">Novel RNAs in Virology (including HIV) and Immune Regulation: Basic Science and Therapeutic Discovery
(R21 Clinical Trial Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The purpose of this Funding Opportunity Announcement (FOA) is to support basic science research, from early exploratory studies to therapeutic discovery and development, in
novel biologically active viral and/or host RNAs involved in virology (including HIV biology) and immune regulation.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Standard dates apply. Expires May 8, 2022.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for June 2019 date: May 22.<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal" style="font-variant-caps: normal;orphans: auto;text-align:start;widows: auto;-webkit-text-size-adjust: auto;-webkit-text-stroke-width: 0px;word-spacing:0px">
<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DMH-2D20-2D120.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=osVPvOb-4iW2UyorY4RY4F5XkVaeHdJ0EzIItQMLBrU&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">This Funding Opportunity Announcement (FOA) encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be
held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or
novel analytic methods, data science techniques, and machine learning approaches. Support may also be requested to prepare and submit existing data into any of the BRAIN Initiative data archives. Investigators should not underestimate the time and effort that
may be necessary to curate or harmonize data. Analyzed data, models and analytical tools generated under this FOA are expected to be deposited into an appropriate data archive. Since the BRAIN Initiative data archives are mostly making the data available to
the research community through cloud-based storage, depositing the analyzed data, models and tools are expected to enhance opportunities to create a data sandbox where investigators can easily compare the results of their analysis with those from other research
groups. The goal of this FOA is to promote studies that will significantly advance new discoveries and accelerate the pace of research of the BRAIN Initiative through harnessing the big data and machine learning opportunities. Awardees are expected to enhance
the value of existing data, improve the overall data integration and analysis capability, and strengthen the statistical power and rigor and reproducibility of BRAIN Initiative related data.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 6, 2019 and June 11, 2020.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents for September 2019 date: August 22.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></p>
<p class="MsoNormal"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DRM-2D19-2D005.html&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=pkY4lbPtPOknLmLefVF1kx6QfSgm6S_JFcX9hQL2gjg&e=" target="_blank"><span style="font-size:12.0pt;font-family:Palatino">NIH Director’s Pioneer Award Program (DP1 Clinical Trial Optional)</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino;color:black">The
</span><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__commonfund.nih.gov_pioneer&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=E-TbHv1PbjxxilRLwSkkTQlXkH6LS3j_jc1q2wEQpe8&e="><span style="font-size:12.0pt;font-family:Palatino">NIH Director’s Pioneer Award Program</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"> supports individual scientists of exceptional
creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity
of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics
relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering,
the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the
</span><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__commonfund.nih.gov_highrisk_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=74QDn5yXWna7DUQObYCmG-vsq972N2BWYMX-spgAzxU&e="><span style="font-size:12.0pt;font-family:Palatino">High-Risk, High-Reward Research program</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black"> of the
</span><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__commonfund.nih.gov_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=aYuhBouYrYcyyN1S7S-kbq6Vbmy8BhFIGSMTrX7-6Z0&s=hs0bwQCXyNmzzdNJ8y8uR38WlGgRqvm81tGcdDJV_jU&e="><span style="font-size:12.0pt;font-family:Palatino">NIH Common Fund</span></a><span style="font-size:12.0pt;font-family:Palatino;color:black">.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">Due September 9, 2019.
</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:red">Med-RA deadline to receive draft documents: August 23.</span></b><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e="><b><span style="font-size:12.0pt;font-family:Palatino;color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b><span style="font-size:12.0pt;font-family:Palatino;color:black">.</span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
</div>
</body>
</html>